Pneumocystis jirovecii following rituximab

Rheumatology (Oxford). 2021 Jun 17;60(Suppl 3):iii70-iii72. doi: 10.1093/rheumatology/keab040.

Authors

Megan Rutter^{1

2}, Mithun Chakravorty², Peter C Lanyon^{1

2}, Philip Courtney²

Affiliations

¹ Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
² Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

PMID: 34137871
DOI: 10.1093/rheumatology/keab040

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Female
Granulomatosis with Polyangiitis / drug therapy
Humans
Immunologic Factors / adverse effects*
Immunosuppression Therapy / adverse effects
Middle Aged
Pneumocystis carinii
Pneumonia, Pneumocystis / chemically induced*
Pneumonia, Pneumocystis / microbiology
Rituximab / adverse effects*

Substances

Immunologic Factors
Rituximab